Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL18AP2 is classified as a pseudogene and is annotated as ribosomal protein L18a pseudogene 2 in the human genome[2][4][6]. Unlike true ribosomal protein genes (such as RPL18A), RPL18AP2 does not encode a functional protein and has no established biological function or role in therapeutic targeting. Pseudogenes like RPL18AP2 arise from duplication or retrotransposition events of their parent genes but typically accumulate mutations that prevent them from producing functional proteins[4][6]. There is no evidence that RPL18AP2 is involved in disease, interacts with drugs, or is used as a biomarker. Additionally, it is not considered a member of key molecular families such as enzymes, receptors, or transcription factors. In scientific and biomedical contexts, RPL18AP2 should not be selected as a therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L18a pseudogene 2 (RPL18AP2).